Primrose Therapeutics

Primrose Therapeutics was a private biotechnology company founded in 2010 in New York that focused on developing therapeutics for polycystic kidney disease. Publicly available company profiles describe the company as targeting PKD broadly, and patent materials associated with the company indicate a small-molecule approach involving receptor tyrosine kinase modulation for PKD. The company appears to have remained at a preclinical stage, with no clearly documented clinical-stage pipeline or approved products. Primrose Therapeutics was acquired in September 2011, and subsequent biographies of founder Eric Rowinsky as well as transaction databases indicate the acquirer was Stemline Therapeutics. The company therefore appears to be a historical, no-longer-independent biotech rather than an active operating business.